Your browser doesn't support javascript.
loading
What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care.
Dale, Megan; Bell, Sarah F; O'Connell, Susan; Scarr, Cerys; James, Kathryn; John, Miriam; Collis, Rachel E; Collins, Peter W; Carolan-Rees, Grace.
Afiliação
  • Dale M; Cedar, Cardiff & Vale University Health Board, Cardiff, UK. megan.dale@wales.nhs.uk.
  • Bell SF; Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.
  • O'Connell S; Cedar, Cardiff & Vale University Health Board, Cardiff, UK.
  • Scarr C; Department of Obstetrics and Gynaecology, Cardiff and Vale University Health Board, Cardiff, UK.
  • James K; Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.
  • John M; Department of Emergency Medicine, Aneurin Bevan University Health Board, Newport, UK.
  • Collis RE; Department of Anaesthetics, Intensive Care and Pain Medicine, Cardiff and Vale University Health Board, Cardiff, UK.
  • Collins PW; Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
  • Carolan-Rees G; , Scarborough, UK.
Pharmacoecon Open ; 6(6): 847-857, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36066836
ABSTRACT
BACKGROUND AND

OBJECTIVE:

A postpartum haemorrhage quality improvement initiative (the Obstetric Bleeding Strategy for Wales [OBS Cymru]), including about 60,000 maternities, was adopted across Wales (2017-2018). We performed a cost-consequences analysis to inform ongoing provision and wider uptake.

METHODS:

Analysis was based on primary data from the All Wales postpartum haemorrhage database, with a UK National Health Services perspective, a time horizon from delivery until hospital discharge and no discounting. Costs were based on UK published sources with viscoelastic haemostatic assay costs provided by the OBS Cymru national team. Mean costs per eligible patient (postpartum haemorrhage > 1000 mL) were calculated for OBS Cymru, using the early implementation period as a comparator. Modelling allowed comparisons of three scenarios (two predefined and one post hoc) and implementation in different sizes of maternity unit.

RESULTS:

All analyses demonstrated consistent savings in blood products, critical care and haematology time, and also a reduced occurrence of massive postpartum haemorrhage (> 2500 mL). Incremental postnatal length of stay varied between scenarios, substantially impacting on total costs. Mean incremental cost of OBS Cymru, compared with standard care, across Wales was £18.41 per patient (postpartum haemorrhage > 1000 mL) or - £10.66 if the length of stay was excluded. Modelling a maternity unit of 5000 births per annum, OBS Cymru incurred an incremental cost of £9.53 per patient with postpartum haemorrhage > 1000 mL.

CONCLUSIONS:

OBS Cymru reduces the occurrence of massive postpartum haemorrhage, need for transfusions, quantity of blood products and intensive care. In medium-to-large maternity units (>3000 maternities per annum), the OBS Cymru intervention approaches cost neutrality compared to standard care.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Pharmacoecon Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Pharmacoecon Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido